Please provide your email address to receive an email when new articles are posted on . Corneal allogenic intrastromal ring segments have been described by Jacob and colleagues for the treatment of ...
Please provide your email address to receive an email when new articles are posted on . Keratoconus is a personal area of interest. In this commentary, I will share a few of my current thoughts on the ...
BURLINGTON, Mass.--(BUSINESS WIRE)--Epion Therapeutics (Epion) announced the commencement of its Phase 3 Apricity trials for EpiSmart™, the company’s minimally-invasive keratoconus therapy. This marks ...
The average per-person inflation-adjusted lifetime cost of keratoconus treatment in 2019 was nearly $29,000, with a cumulative economic burden of $3.8 billion, a large retrospective cohort study ...
In a recent study published in Nature Biotechnology, researchers bioengineered corneal tissue for minimally invasive vision restoration. Study: Bioengineered corneal tissue for minimally invasive ...
On Monday, Glaukos Corporation (NYSE:GKOS) received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for ...
The commonly quoted number for the prevalence of keratoconus is 1:2000, which is pretty rare, although it varies by region of the world. Using mandatory health insurance data on 4.4 million patients ...
Keratoconus is a progressive condition that causes the cornea—the clear, front surface of the eye—to thin and become more steeply curved. This can result in blurred vision and other visual distortions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results